Skip to content

GLP-1s & incretins · Metabolic & endocrine

Exenatide

The first GLP-1 receptor agonist — born from Gila-monster venom peptide biology — with formulations ranging from twice-daily to weekly injection.

L5Practice-changingApproved medicineApprovedHigh confidenceLast reviewed 2026-08-23
SC injection

Also known as: Byetta, Bydureon, exendin-4

Evidence passport

Last reviewed 2026-08-23

Evidence level
L5Practice-changing
Confidence
High confidence
Human efficacy
85/100
Human safety
80/100
Regulatory status
Approved medicine
Development
Approved
Routes
SC injection
Evidence base
Includes human data
Furthest stage
Approved
Source curation
Sources fully curated
Clinical maturity
Established GLP-1 medicine family

Overview

Human evidence85/100
Preclinical evidence80/100
Human safety evidence80/100

Clinical maturity: Established GLP-1 medicine family

Routes & formulations

Studied / approved routes

SC injection

All approved products are subcutaneous injections; immediate-release and extended-release formulations differ in schedule — a reminder that GLP-1 describes a class with meaningfully different products.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

Approved

What it is

A synthetic version of exendin-4, a peptide found in Gila-monster saliva that resists DPP-4 breakdown and activates the human GLP-1 receptor.

What people claim

  • Improves blood-glucose control in type 2 diabetes
  • Modest weight reduction in treated patients

What the evidence actually says

A large trial programme and nearly two decades of clinical use established its glycaemic role. It also anchors a key comparison: GLP-1 medicines differ in schedule, magnitude of effect and evidence depth — the class label is not a uniform verdict.

Human evidence

  • Pivotal randomised trials in type 2 diabetes for immediate- and extended-release products.
  • Cardiovascular outcome data for the extended-release formulation.

Preclinical evidence

  • GLP-1-receptor pharmacology originating in exendin-4 biology.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • GLP-1-receptor agonism enhances glucose-dependent insulin secretion, suppresses glucagon and slows gastric emptying.

Safety and unknowns

  • Labelled class effects include gastrointestinal symptoms and a pancreatitis warning.
  • Thyroid C-cell tumours in rodent studies are a labelled class consideration for the extended-release product; human relevance is not established.

Cancer relevance

Monitored in trials; not demonstrated in humans

Rodent thyroid C-cell tumour findings are a labelled mechanistic class consideration for the extended-release formulation; a causal human risk is not established.

Regulatory status

FDA-approved (Byetta; the Bydureon family) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Different formulations carry different dosing schedules and label details.

Evidence grade

L5Practice-changingHigh confidence

Replicated large randomised trials, pivotal Phase 3 programmes, or a major regulatory decision.

What would change our rating?

  • Not applicable at this evidence tier.

References and sources

Sources fully curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

No recorded changes yet. Baseline position set on 2026-08-23.

Related claims we’ve checked

MisleadingL5Practice-changingGLP-1s & incretins

“All GLP-1 peptide drugs are weekly injections.”

Misleading — the class spans different schedules and even routes.

  • Exenatide and lixisenatide are approved GLP-1 medicines with more frequent injection schedules than the weekly agents.
  • Oral semaglutide (Rybelsus) is an approved daily tablet, while injectable semaglutide is weekly — the same molecule in different formulations.
  • Schedules and routes vary by product and formulation; this registry provides no dosing instructions, but the 'all weekly injections' shortcut is factually wrong.
Last reviewed 2026-08-23Compound profile